The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...

Amgen's potential anti-obesity medicine, MariTide, is currently in phase 2 studies. It looks like one of the more promising ...

Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...

After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data ...

Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Amgen addresses safety concerns for its weight loss drug MariTide after new data suggests a potential 4% reduction in bone ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

As Modern Healthcare reports, CMS has relaxed supervision requirements for physical and occupational therapist assistants from “direct” to “general.” The change could help health systems manage ...